Table 3.
The differences of clinical recognized serum tumor markers between patients with and without OM under different classifications
A. Non-lymph node metastasis | ||||
Clinical features | OM group (n=21) | NOM group (n=432) | t | P-value |
TC (mmol/L) | 4.26±0.52 | 4.14±0.98 | 0.952 | 0.350 |
TG (mmol/L) | 1.16±0.47 | 1.29±1.72 | −0.350 | 0.727 |
HDL (mmol/L) | 1.38±0.34 | 1.16±0.37 | 2.695 | 0.007 |
LDL (mmol/L) | 2.39±0.39 | 2.50±0.79 | −1.220 | 0.233 |
B. Female | ||||
Clinical features | OM group (n=5) | NOM group (n=267) | t | P-value |
TC (mmol/L) | 4.26±0.46 | 4.42±1.03 | −0.363 | 0.717 |
TG (mmol/L) | 0.98±0.27 | 1.28±0.72 | −0.930 | 0.353 |
HDL (mmol/L) | 1.50±0.29 | 1.28±0.39 | 1.285 | 0.200 |
LDL (mmol/L) | 2.63±0.18 | 2.65±0.82 | −0.141 | 0.891 |
C. Male | ||||
Clinical features | OM group (n=16) | NOM group (n=415) | t | P-value |
TC (mmol/L) | 4.26±0.55 | 4.11±0.97 | 1.021 | 0.320 |
TG (mmol/L) | 1.21±0.52 | 1.27±1.72 | −0.128 | 0.898 |
HDL (mmol/L) | 1.34±0.36 | 1.13±0.35 | 2.345 | 0.019 |
LDL (mmol/L) | 2.31±0.41 | 2.50±0.82 | −1.772 | 0.092 |
D. Non-lymph node metastasis + male | ||||
Clinical features | OM group (n=16) | NOM group (n=258) | t | P-value |
TC (mmol/L) | 4.26±0.55 | 4.01±0.89 | 1.701 | 0.104 |
TG (mmol/L) | 1.21±0.52 | 1.29±2.13 | −0.152 | 0.880 |
HDL (mmol/L) | 1.34±0.36 | 1.10±0.34 | 2.733 | 0.007 |
LDL (mmol/L) | 2.31±0.41 | 2.44±0.76 | −1.188 | 0.247 |
E. Whole | ||||
Clinical features | OM group (n=21) | NOM group (n=682) | t/Z | P-value |
TC (mmol/L) | 4.26±0.52 | 4.23±1.00 | 0.206a | 0.839 |
TG (mmol/L) | 1.16±0.47 | 1.27±1.42 | −0.271 | 0.787 |
HDL (mmol/L) | 1.38±0.34 | 1.19±0.37 | 2.322 | 0.021 |
LDL (mmol/L) | 2.39±0.39 | 2.56±0.82 | −1.910 | 0.067 |
Notes: aComparison between OM group and NOM metastases group by nonparametric sum up tests. P<0.05 was considered statistically significant.
Abbreviations: OM, ocular metastasis; NOM, non-ocular metastasis; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein.